KaloBios Pharmaceuticals Inc (OTC:KBIOQ) announced the adoption of a new pricing model that will guide the company’s strategy and operations. This framework applies to …
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) announced that it has decided to withdraw its appeal of the decision by the Nasdaq listing qualifications staff to delist the Company’s …
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), announced that on January 7, 2016, Ronald Barliant and Dr. Cameron Durrant MD, MBA, were elected as independent directors to …
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) plunged 53% in pre-market trading this morning to $11.03 after CEO Martin Shkreli was arrested earlier today on security fraud …
Ambarella Inc (NASDAQ:AMBA) shares fall 7.55% to $53.
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), announced that it has signed an agreement to acquire a benznidazole program for the treatment of Chagas Disease fromSavant …
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) announced that Patrick Crutcher has been appointed Head of Business Development, Chris Thorn has been appointed interim Chief Financial …
Sunedison Inc (NYSE:SUNE) shares are up nearly 5% to $3.41, rebounding from falls on Wednesday after UBS research analyst Julien Dumoulin Smith downgraded the …
by Terry Chrisomalis Valeant Pharmaceuticals Intl Inc On November 18, 2015, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) had received approval for two new indications of …
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) shares are trading down nearly 2% this morning. The biotech company released a Form 8-K yesterday after the close, notifying the …
